Redica Responds is an article series where we take common/unique questions from customers and industry events and answer them with our data. Use the following link to look at all previous Redica Responds articles.
How frequent are FDA 483 observations involving clinical investigators’ paper record controls?
As in other pharma operations (GMP comes to mind), clinical investigators must adhere to data integrity practices. Data integrity issues in the course of clinical trials have resulted in delayed approval of products, in addition to negative media attention.
Paper record controls are one data integrity area of concern when it comes to clinical trials.
Using Redica, we can pull 483 primary observations involving paper record controls issued to clinical investigators over a period of time, in this case, 2012-2022.
So, how many 483s were issued? Redica shows 21 issued over the previous ten years.
In general, Redica Systems data show that data integrity 483 observations appeared in more than half of the observations issued to clinical trial investigators of human drug clinical studies in the past 20 years. The top categories of data integrity deficiencies fall into three categories:
- Issues with the original data
- Data is not attributable
- Data was not accurate
For more information on how our GCP Expert Model provides a window into clinical investigator data integrity trends, we recommend viewing the recording of the webinar, “FDA GCP Inspection Trends Identified Using AI,” featuring a prerecorded presentation by Redica Systems Senior GMP Quality Expert Jerry Chapman.
GCP Inspection Preparation
Redica’s actionable intelligence can help you stay on top of inspection preparation. Here is how our GCP Expert Model can help you:
Vendor Quality—Intelligence to identify and control risk with your critical GCP vendors
Inspection Preparation—Access deeper intelligence about inspection trends and inspector tendencies
Contact us today for a demonstration of our GCP Expert Model.
Data Integrity and Your Clinical Investigator: What the Data Shows
The Components of “Responsibilities of the Investigator” Observations
Extracting Specific Protocol Violations from Warning Letter Citations
Data Integrity Concerns Discovered in Gene Therapy Product Submissions
Subscribe to Redica Insights
Get quality and compliance insights from our experts in your inbox
Or request a demo to talk with one of our team members.